AGS-16C3F

N/A

Report date: 2025/10/02 20:00:08

Base Information

Drug NameAGS-16C3F
Drug Alias NameAGS-16FAGS-16C3FAGS-16M8F
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAF payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin inhibitorsEctonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitors
TargetsTubulinEctonucleotide pyrophosphatase/phosphodiesterase family member 3
Therapy Area/IndicationsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAgensys Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstellas Pharma IncAgensys IncAstellas Pharma Global Development Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A